Company intelligence
Outsourced Pharma
Strategic intelligence for biopharma executives navigating outsourced drug development, manufacturing, and operations.
About Outsourced Pharma
Outsourced Pharma is built for biopharma and pharma executives who make outsourcing decisions: development leads, manufacturing directors, and operations executives evaluating CDMO, CRO, and CMO partners across the drug development lifecycle. We cover contract manufacturing, clinical outsourcing, regulatory strategy, supplier relationships, and the strategic and operational decisions that determine whether outsourcing works. Our editorial goes beyond vendor directories and press releases - we surface the intelligence that experienced operators actually need. Follow Outsourced Pharma for expert perspectives, in-depth editorial, and industry events, or join the community at https://www.outsourcedpharma.com/
Verified activity
Signals from Outsourced Pharma
6 published signals
Research & Knowledge
Outsourced Pharma published an article by Arnaud Deladeriere, Ph.D., in collaboration with Cell&Gene Foundry, discussing cell therapy developers' lack of full product understanding.
Reported by Louis Garguilo
Presence & Recognition
Outsourced Pharma attended the ADC Capabilities Update hosted by Catalent to learn about the integrated ADC and bioconjugate development platform spanning the full product lifecycle.
Reported by Outsourced Pharma
Legal & Regulatory
Outsourced Pharma noted that the Bloomington, Indiana facilities owned by Catalyst until sold to Novo Nordisk in December 2024 have not solved its quality issues, as confirmed by the FDA in April.
Reported by Louis Garguilo
Presence & Recognition
Outsourced Pharma Deputy Editor Jeffrey S. Buguliskis sat down with Krishnan Ramanathan, CEO of the Gates Medical Research Institute, to discuss global health drug development and sustainable manufacturing.
Reported by Outsourced Pharma
Presence & Recognition
Outsourced Pharma welcomed Dr. Michael Kraich of Boehringer Ingelheim for a live discussion on biologics supply resilience, business continuity, and manufacturing readiness.
Reported by Outsourced Pharma
Research & Knowledge
Outsourced Pharma presents the Contract Manufacturing: Opportunities and Threats (CMOT) Report to its readers each month in conjunction with GlobalData Plc.
Reported by Louis Garguilo